NCT00110929View on ClinicalTrials.gov

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

PHASE2CompletedINTERVENTIONAL
Enrollment

850

Participants

Timeline

Start Date

November 30, 2002

Conditions
End Stage Renal Disease
Interventions
DRUG

AMG 073

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY